TransMedics up 6% as 2025 revenue guidance exceeds consensus

by


Quarterly results

CharlieAJA

  • TransMedics (NASDAQ:TMDX) is ~6% higher in after-hours trading Thursday after posting 2025 revenue guidance above the consensus figure.
  • The medtech sees revenue this year of $530M-$552M. Consensus is $521.62M.
  • In Q4, TransMedics (NASDAQ:TMDX) beat on both lines.
  • In the quarter, net


Leave a Comment